PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>Tirzepatide>>side-effects
Approved medicine

Tirzepatide Side Effects: What the Label Reports

A summary of tirzepatide’s adverse-effect profile from its label and registrational trials — common effects, warnings, and active surveillance topics.

Common effects

Nausea, diarrhea, vomiting, and constipation are the most frequent events, dose-related and most intense during escalation. Injection-site reactions occur at low rates.

Labeled warnings

The label carries the class medullary thyroid carcinoma/MEN2 contraindication, pancreatitis and gallbladder warnings, acute kidney injury risk via dehydration, hypersensitivity warnings, and hypoglycemia caution when combined with insulin or secretagogues.

Gastroparesis and anesthesia

Delayed gastric emptying has procedural implications (residual gastric content despite fasting); guidance for peri-procedure management is part of the label.

Perspective

Discontinuation from adverse events in trials was low single-digit percentage at approved maintenance doses — tolerability that is dose-escalation-dependent, like the efficacy.

Educational content only — not medical advice. Dosing and treatment decisions belong with the approved label and a prescriber.

References

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. [source]
  2. ClinicalTrials.gov — registered tirzepatide studies. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement